Stock PTCT PTC THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
36.36 USD +1.54% Intraday chart for PTC Therapeutics, Inc. -2.26% +31.93%
May. 24 Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing MT
May. 21 Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PTC Therapeutics to Participate at Upcoming Investor Conference
PR
PTC Therapeutics Announces Validation of Sepiapterin European MAA
PR
Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing
MT
Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating
MT
Raymond James Upgrades PTC Therapeutics to Market Perform From Underperform
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
MT
Sector Update: Health Care
MT
PTC Therapeutics Says European Commission Seeking Review of Negative Opinion on Translarna
MT
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
PR
Transcript : PTC Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM
Sector Update: Health Care Stocks Steady Premarket Tuesday
MT
Sector Update: Health Care
MT
PTC Therapeutics Gets FDA Priority Review for Upstaza Biologics License Application
MT
PTC Therapeutics Gets FDA Priority Review of Upstaza Gene Therapy
DJ
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PR
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza
CI
PTC Therapeutics : Corporate Presentation – May 2024
PU
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR
North American Morning Briefing : More Earnings -2-
DJ
Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTCT Stock
  4. News PTC Therapeutics, Inc.